<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155515</url>
  </required_header>
  <id_info>
    <org_study_id>TGDAG-C-3</org_study_id>
    <nct_id>NCT04155515</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients</brief_title>
  <official_title>A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in
      Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected
      Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of TG-2349 in combination with
      DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I infected patients.
      Approximately 360 subjects will be enrolled in this study and divided into 2 groups:

      Group 1: Chronic hepatics C virus (HCV) genotype 1 infected, non-cirrhotic subjects.

      Group 2: Chronic hepatics C virus (HCV) genotype 1 infected, cirrhotic subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">September 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The non-cirrhotic, HCV genotype 1 infected subjects will be assigned to Group 1. The cirrhotic, HCV genotype 1 infected subjects will be assigned to Group 2. The subjects in Group 1 and 2 will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of antiviral efficacy (HCV RNA &lt; lower limit of quantification, target detected or target not detected) at 12 weeks after the end of treatment</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
    <description>To evaluate the antiviral efficacy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Chronic Hepatics C Virus (HCV) Genotype 1</condition>
  <condition>Non-Cirrhotic</condition>
  <condition>Cirrhosis</condition>
  <condition>Treatment naïve</condition>
  <arm_group>
    <arm_group_label>Non-cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-2349</intervention_name>
    <description>TG-2349 400mg</description>
    <arm_group_label>Cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
    <arm_group_label>Non-cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAG181</intervention_name>
    <description>DAG181 200mg</description>
    <arm_group_label>Cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
    <arm_group_label>Non-cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 1000mg/1200mg</description>
    <arm_group_label>Cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
    <arm_group_label>Non-cirrhotic, HCV genotype 1 infected subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Before starting the study, an informed consent form (ICF) approved by the
             Institutional Review Board (IRB) is obtained from the subject or his/her legal
             representative；

          2. Male or female, and ≥18 years of age inclusive when signing ICF；

          3. Body mass index (BMI) in the range of 18.0 to 35.0kg/m2 and body weight ≥ 40 kg at
             Screening；

          4. Presence of chronic hepatitis C (CHC) as documented below: (1)A positive anti-HCV
             antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months
             prior to the Baseline/Day 1 visit or, (2) A liver biopsy performed prior to the
             Baseline/Day 1 visit with evidence of chronic HCV infection；

          5. Positive for anti-HCV antibody at Screening；

          6. Presence of an HCV RNA level ≥ 1 x 10^4 IU/mL at Screening as determined by the
             Central Laboratory；

          7. Presence of genotype 1a, 1b, or 1a/1b combination HCV-infection at Screening as
             determined by the Central Laboratory；

          8. HCV treatment naïve defined as no prior therapy with any interferon (IFN), ribavirin
             (RBV), or other approved or investigational HCV-specific agent；

          9. Without or with cirrhosis: (1) Without cirrhosis as defined as any one of the
             following: (a) Liver biopsy without showing cirrhosis (e.g., Metavir score &lt; F4 or
             Ishak score &lt; 5) within one year prior to Screening or at Screening. (b) FibroScan
             showing cirrhosis or results ≤ 12.5 kPa within six months prior to Screening or at
             Screening. (2) With cirrhosis as defined as any one of the following: (a) Liver biopsy
             showing cirrhosis (e.g., Metavir score = F4 or Ishak score ≥ 5) within one year prior
             to Screening or at Screening. (b) FibroScan showing cirrhosis or results &gt; 12.5 kPa
             within six months prior to Screening or at Screening；NOTICE: If there is liver biopsy,
             liver biopsy results will supersede non-invasive testing results and be considered
             definitive.

         10. ECG without clinically significant abnormalities at Screening；

         11. Subjects must have the following laboratory parameters at Screening: (1) ALT ≤ 10 ×
             the upper limit of normal (ULN). (2) AST ≤ 10 × ULN. (3) Without cirrhosis: Total
             bilirubin ≤ 1.5 × ULN except history of Gilbert's syndrome. If Gilbert's syndrome is
             the proposed etiology, the total bilirubin must ≤ 2 × ULN. With cirrhosis: Total
             bilirubin ≤ 2 × ULN. (4) Platelet count ≥ 90,000 cells/mm3. (5) Absolute neutrophil
             count (ANC) ≥ 1,500 cells/mm3. (6) HbA1c ≤ 8.5%. (7) Creatinine clearance (CLcr) ≥ 50
             mL /min, as calculated by the Cockcroft-Gault equation. (8) Hemoglobin ≥ 110 g/L for
             female subjects; ≥ 120 g/L for male subjects. (9) Without cirrhosis Albumin ≥ 3.5
             g/dL；With cirrhosis Albumin ≥30g/L. (10) Without cirrhosis INR ≤ 1.5 x ULN；With
             cirrhosis INR ≤ 1.7 x ULN. (11) Alpha fetoprotein (AFP)&lt;100 ng/mL；20ng/mL≤AFP≤100ng/mL
             need to take Liver Ultrasonic testing to exclude subjects with suspicious liver cancer
             cells. (12) Anti-nuclear antibodies (ANA) ≤ 1:320；

         12. A female subject is eligible to enter the study if it is confirmed that she is: (1) Of
             non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries
             removed or medically documented ovarian failure, or are postmenopausal - women &gt; 50
             years of age with cessation (for ≥12 months) of previously occurring menses), or (2)
             Of childbearing potential (Women ≤ 50 years of age with amenorrhea will be considered
             to be of childbearing potential). These women must have a negative serum pregnancy
             test at Screening and agree to consistently and correctly use an approved
             contraceptive method (i.e. abstinence, vaginal ring, cervical cap, contraceptive
             diaphragm, or intrauterine devices) from screening until at least 6 months after the
             last dose of study drug(s)；

         13. Male subjects must agree to consistently and correctly use an approved contraceptive
             method (i.e. abstinence, condom, or spouses using contraceptive drugs, vaginal ring,
             cervical cap, contraceptive diaphragm, or intrauterine devices) from screening until
             at least 6 months after the last dose of study drug(s)；

         14. Male subjects must agree to refrain from sperm donation from screening until at least
             6 months after the last dose of study drug(s)；

         15. Subject must be of generally good health, with the exception of chronic HCV infection,
             as determined by Investigator；

         16. Subject must be able to comply with the dosing instructions for study drug
             administration and able to complete the study schedule of assessments, including all
             required post-treatment visits.

        Exclusion Criteria:

          1. Positive serological test for IgM anti-HAV or anti-HEV antibody at Screening；

          2. Positive serological test for HBsAg at Screening；

          3. Positive test for HIV-1 or HIV-2 at Screening；

          4. Clinically-relevant drug abuse within 12 months of signing the ICF. A positive drug
             screen will exclude subjects unless it can be explained by a prescribed medication;
             the diagnosis and prescription must be approved by Investigator；

          5. Alcohol misuse as defined by an AUDIT score of ≥ 8；

          6. Contraindications to RBV therapy, including hemoglobinopathies (e.g., thalassemia
             major or sickle-cell anemia)；

          7. Pregnant or nursing female or male with pregnant female partner；

          8. Use of any prohibited medications before Baseline/Day 1 visit；

          9. Known hypersensitivity to TG-2349, DAG181, RBV, sulfa drugs, or formulation
             excipients；

         10. Current or prior history of any of the following: (1) Chronic hepatic disorder not
             induced by HCV (including but not limited to Hemochromatosis, Wilson's disease,
             alpha-1 antitrypsin deficiency, cholangitis, autoimmune hepatitis, alcoholic liver
             disease, drug-induced liver disease. (2) Decompensated liver cirrhosis (Child-Pugh
             class B and C). (3) Any dysphagia, malabsorption syndrome, or other gastrointestinal
             disturbances affecting drug absorption. (4) Difficulty with blood collection and/or
             poor venous access for the purposes of phlebotomy. (5) Central nervous system (CNS)
             trauma, seizure disorder, stroke or transient ischemic attack. (6) Solid organ
             transplantation. (7) Significant cardiac disease (including but not limited to the
             myocardial infarction based on ECG and/or clinical history). (8) Significant pulmonary
             disease or porphyria (e.g. lung infiltration or impaired lung function). (9)
             Pancreatitis. (10) Autoimmune disease (systemic lupus erythematosus, rheumatoid
             arthritis, sarcoidosis, psoriasis). (11) Psychiatric hospitalization, suicide attempt,
             and/or a period of disability as a result of their psychiatric illness within the last
             5 years. (12) Malignancy within 5 years prior to Screening, with the exception of
             specific cancers that are entirely cured by surgical resection (basal cell skin
             cancer, etc). Subjects under evaluation for possible malignancy are not eligible. (13)
             Serious acute drug allergy (such as anaphylaxis or hepatotoxicity) or serious skin
             hypersensitive reaction (such as vesicular rash, Stevens Johnson Syndrome)；

         11. As determined by Investigator, a subject that would affect the therapy, evaluation or
             compliance with the protocol is not suitable to take part in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang LiWen, master</last_name>
    <phone>+889281777020</phone>
    <phone_ext>1227</phone_ext>
    <email>lwchang@taigenbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lai Wei, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatics C Virus (HCV) Genotype 1</keyword>
  <keyword>Non-Cirrhotic</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>TG-2349</keyword>
  <keyword>DAG181</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Yimitasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

